
|Videos|April 8, 2014
Diagnosing Prostate Cancer: The Bioptic Gun, PET/CT Scans, and Mapping Biopsies
Author(s)E. David Crawford, MD
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer.
Advertisement
Clinical Pearls
E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses diagnosing prostate cancer. Crawford presented at the7th Annual Interdisciplinary Prostate Cancer Congress™on defining candidates for active surveillance and modifying biopsy techniques.
- The development of the bioptic gun has revolutionized the diagnosis of prostate cancer but has also created controversy.
- PET and CT scans are a waste in localized prostate cancer; physicians are not worried about the disease spreading.
- Low-risk patients are now being defined better with transperineal 3D mapping biopsies, which are done under the scrotum at 5 mm intervals.
- Once 3D reconstruction of the prostate is completed, a physician can decide whether to treat with laser ablation, freezing, or definitive therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5



















